Sistema to establish biotech R&D lab at the International Medical Cluster in Solkovo

Moscow, Russia – 6 June 2019 – – Sistema PJSFC (“Sistema” or the “Corporation”) (LSE: SSA, MOEX: AFKS), a publicly traded diversified Russian holding company, and the International Medical Cluster (IMC) Foundation have signed a partnership agreement that calls for the parties to cooperate on a project to establish a full-fledged, multidisciplinary biotechnology research and development laboratory at the International Medical Cluster in Skolkovo. The agreement was signed at the St. Petersburg International Economic Forum by Sistema Managing Partner Artem Sirazutdinov and IMC CEO Mikhail Yugai.

Sistema’s biotech lab will be used to conduct scientific research activities in the areas of genetic diagnostics, predictive medicine, drug development and integration of modern technologies into clinical practice.

The IMC Foundation commits to support Sistema as it becomes a resident of the IMC and will ensure that all necessary infrastructure is supplied for the establishment of the laboratory on the site. For its part, Sistema will invest funds in equipment and technical outfitting of the R&D lab, as well as retaining highly qualified professionals to implement the project.

Sistema Managing Partner Artem Sirazutdinov said: “The development of Russian healthcare and pharmacology are priority investment areas for Sistema. Early diagnosis of genetic diseases and ensuring that cell-based treatments become routine practice are just some of the challenges set before our R&D lab. We are delighted to be partnering with the IMC Foundation to deliver on this socially important project that will improve quality of life for our countrymen.” 

IMC CEO Mikhail Yugai: “The IMC's most important job is to create a conducive environment for the development of Russian healthcare. Attracting best international practice in medicine into Russia is not enough, because today medicine can exist and develop only on the basis of three areas: education, clinical research and experienced manufacturing. We are pleased that the establishment of this R&D lab is being undertaken by an organisation that dedicates particular attention to the development of Russian healthcare. Establishing a biotech lab to the highest international standards will provide for the resolution of timely tasks targeted on the development of personalised medicine and tools for early diagnosis of genetic diseases.”


For further information, please visit www.sistema.com or contact:

Investor Relations

Nikolai Minashin

Tel: +7 (495) 730 66 00


Public Relations

Sergey Kopytov

Tel.: +7 (495) 228 15 32





Sistema PJSFC is a publicly-traded diversified Russian holding company serving over 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2018 was RUB 773.9 bn; total assets equalled RUB 1.1 trn as of 31 December 2018. Sistema’s global depositary receipts are listed under the “SSA” ticker on the London Stock Exchange. Sistema’s ordinary shares are listed under the “AFKS” ticker on the Moscow Exchange. Website: www.sistema.com.

International Medical Cluster on the territory of the Skolkovo Innovation Center  is a social project of the Government of City of Moscow in the field of healthcare. The project is aimed a significantly raising the quality and efficiency of medical services in Russia. The cluster is unique in that medical institutions from OECD countries can offer medical services, drugs and equipment on the territory of the cluster without a Russian Federation certificate if they have received all relevant approvals in their home country. The IMC occupies 57.6 hectares at Skolkovo. As the IMC project is rolled out 1015 medical institutions from OECD countries will open their doors, and as a result as many as 300,000 patients will receive top-tier medical care based on the latest achievements in healthcare.

Back To List

Contact PR

Sergey Kopytov
Tel.: +7 (495) 228 15 27

Eleonora Veitsman
Tel.: +7 (495)  730-17-05

Dmitry Kolchugin
Tel.: +7 (495)  692-10-88